Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023;69(3):312-320.
doi: 10.1159/000526480. Epub 2022 Oct 21.

External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative Bacteremia

Adi Turjeman  1   2 , Fidi Koppel  3 , Erica Franceschini  4 , Dafna Yahav  2   5 , Giovanni Dolci  4 , Erica Bacca  4 , Tanya Babich  1   2 , Ebtehal Khazem  6 , Eyal Baum  3 , Rima Nassar  3 , Roni Bitterman  3 , Yael Dishon-Benatta  3   7 , Nasreen Hassoun-Kheir  3 , Antonella Santoro  4 , Noa Eliakim-Raz  1   2 , Itamar Poran  1 , Barak Pertzov  2   8 , Anat Stern  3 , Yaakov Dickstein  3 , Elias Maroun  3 , Marina Raines  3 , Marianna Meschiari  4 , Jihad Bishara  2   5 , Elad Goldberg  9 , Claudia Venturelli  10 , Mario Sarti  10 , Cristina Mussini  4 , Mical Paul  3   7 , Leonard Leibovici  1   2
Affiliations
Observational Study

External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative Bacteremia

Adi Turjeman et al. Gerontology. 2023.

Abstract

Introduction: Reports regarding the external validity of randomized controlled trials (RCTs) are scarce. We aimed to assess the population external validity of an investigator-initiated RCT on the duration of antibiotics for the treatment of Gram-negative bacteremia by comparing patients included in the RCT to patients that were not included in the trial.

Methods: Hospitalized patients with Gram-negative bacteremia were recruited into an RCT and randomized to receive 7 or 14 days of covering antibiotic therapy in Israel and Italy from 2013 to 2017. In a concomitant observational study, RCT participants were compared with patients who fulfilled the inclusion criteria but were not included in the trial due to participation in other trials, discharge before approached by researchers, refusal to participate, or unwillingness of the treating physician to allow participants' recruitment.

Results: Six hundred and four RCT patients were compared with 613 nonincluded patients. Almost 50% of nonincluded patients (288/613) were dependent on others for activities of daily living at baseline compared to 37.7% of RCT participants (228/604). Dementia was nearly 2-fold more frequent in nonincluded patients than those included (5.9% [36/613] versus 3.6% [22/604], p = 0.07). Patients who were not included in the RCT were more likely to acquire their infection in the hospital (53.3% [327/613] versus 29.1% [176/604], p < 0.001). The primary composite outcome of mortality, clinical failure, readmissions, or extended hospitalization at 90 days occurred in 353 of 613 nonincluded patients (57.6%) compared to 299 of 604 RCT participants (49.6%), p = 0.005. However, on multivariate analysis noninclusion in the RCT was not an independent risk factor for clinical failure and mortality.

Conclusions: RCTs, even with broad eligibility criteria, do not represent the whole spectrum of patients and leave out a population with more severe illness for whom the evidence is lacking.

Keywords: Dementia; External validity; Gram-negative bacteremia; Mobility; Randomized controlled trial.

PubMed Disclaimer

Publication types

Substances

LinkOut - more resources